Pixabay- DeltaworksSwiss Noema Pharma AG has cashed in a CHF27m extention to its Series B financing that is used to advance four Phase II programmes in neurology.
ADVERTISEMENT
Swiss Noema Pharma AG has cashed in a CHF27m extention to its Series B financing that is used to advance four Phase II programmes in neurology.